Appendix Table A9.
Distribution of Symptom Survey Frequency Scores for Individual Questionnaire Items at Baseline and Follow- up Visits by Treatment Group.
| Baseline | 4 weeksa | 8 weeksa | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||
| Binocular Treatment | Continued Spectacles | Binocular Treatment | Continued Spectacles | Binocular Treatment | Continued Spectacles | |||||||
|
|
||||||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
|
| ||||||||||||
| Per Group (N) | 92 | 90 | 88 | 83b | 86 | 84 | ||||||
|
| ||||||||||||
| Blurred Vision | ||||||||||||
| Never | 62 | 67% | 61 | 68% | 72 | 82% | 71 | 86% | 74 | 86% | 62 | 74% |
| Almost never | 11 | 12% | 10 | 11% | 10 | 11% | 6 | 7% | 5 | 6% | 17 | 20% |
| Sometimes | 17 | 18% | 12 | 13% | 5 | 6% | 4 | 5% | 7 | 8% | 5 | 6% |
| Often | 2 | 2% | 5 | 6% | 1 | 1% | 2 | 2% | 0 | 0% | 0 | 0% |
| Almost always | 0 | 0% | 2 | 2% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
|
| ||||||||||||
| Eyestrain | ||||||||||||
| Never | 57 | 62% | 47 | 52% | 53 | 60% | 58 | 70% | 58 | 67% | 58 | 69% |
| Almost never | 19 | 21% | 18 | 20% | 15 | 17% | 19 | 23% | 16 | 19% | 20 | 24% |
| Sometimes | 12 | 13% | 19 | 21% | 17 | 19% | 6 | 7% | 12 | 14% | 6 | 7% |
| Often | 4 | 4% | 6 | 7% | 3 | 3% | 0 | 0% | 0 | 0% | 0 | 0% |
| Almost always | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
|
| ||||||||||||
| Headache | ||||||||||||
| Never | 59 | 64% | 47 | 52% | 60 | 68% | 68 | 82% | 62 | 72% | 65 | 77% |
| Almost never | 19 | 21% | 27 | 30% | 14 | 16% | 13 | 16% | 13 | 15% | 17 | 20% |
| Sometimes | 12 | 13% | 15 | 17% | 9 | 10% | 1 | 1% | 10 | 12% | 2 | 2% |
| Often | 2 | 2% | 0 | 0% | 5 | 6% | 1 | 1% | 1 | 1% | 0 | 0% |
| Almost always | 0 | 0% | 1 | 1% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
|
| ||||||||||||
| Looking over spectacles c | ||||||||||||
| Never | 30 | 33% | 34 | 38% | 44 | 50% | 40 | 48% | 38 | 44% | 40 | 48% |
| Almost never | 23 | 25% | 21 | 23% | 17 | 19% | 19 | 23% | 16 | 19% | 17 | 20% |
| Sometimes | 25 | 27% | 24 | 27% | 19 | 22% | 17 | 20% | 26 | 30% | 23 | 27% |
| Often | 11 | 12% | 9 | 10% | 6 | 7% | 6 | 7% | 5 | 6% | 2 | 2% |
| Almost always | 3 | 3% | 2 | 2% | 2 | 2% | 1 | 1% | 1 | 1% | 2 | 2% |
|
| ||||||||||||
| Taking off spectacles c | ||||||||||||
| Never | 28 | 30% | 39 | 43% | 43 | 49% | 46 | 55% | 45 | 52% | 44 | 52% |
| Almost never | 34 | 37% | 27 | 30% | 26 | 30% | 24 | 29% | 28 | 33% | 30 | 36% |
| Sometimes | 24 | 26% | 19 | 21% | 15 | 17% | 11 | 13% | 8 | 9% | 7 | 8% |
| Often | 5 | 5% | 4 | 4% | 4 | 5% | 1 | 1% | 5 | 6% | 3 | 4% |
| Almost always | 1 | 1% | 1 | 1% | 0 | 0% | 1 | 1% | 0 | 0% | 0 | 0% |
a
The exact Wilcoxon rank sum test was used to compare symptom frequency at 4 weeks (P = .59 for blurred vision; P = .06 for eyestrain; P = .02 for headache; P = .98 for looking over spectacles; P = .30 for taking off spectacles) and at 8 weeks (P = .08 for blurred vision; P = .63 for eyestrain; P = .27 for headache; P = .52 for looking over spectacles; P = .83 for taking off spectacles) between the treatment groups.
b
One participant in the control treatment group did not have a completed Symptom Survey at the 4-week visit.
c
There were no responses that spectacles were not worn.